CAMBRIDGE, Mass. — Enveric Biosciences said preclinical testing showed no photoreactive potential for EB-003, its lead neuroplastogen drug candidate being developed for neuropsychiatric disorders including depression, anxiety and PTSD.
The Cambridge-based biotechnology company said the in vitro analysis evaluated whether EB-003 could pose a phototoxicity risk, meaning whether the compound could become harmful when exposed to ultraviolet light. Phototoxicity testing is part of preclinical safety assessment and is required under regulatory guidance for certain drug candidates.
Enveric said the results further reduce development risk for EB-003 as the company prepares to move the program toward first-in-human Phase 1 clinical trials.
EB-003 is designed to selectively engage both 5-HT2A and 5-HT1B receptors. The company said the compound is intended to provide fast-acting and durable antidepressant and anti-anxiety effects while being suitable for outpatient treatment.
Some photoactive compounds can cause reactions such as sunburn-like skin responses, rashes or blistering in tissues exposed to sunlight, including the skin and eyes. Enveric said the latest testing did not indicate that EB-003 has that type of photoreactive potential.
“The demonstration of limited potential for phototoxicity enhances the favorable safety profile of EB-003,” said Joseph Tucker, Ph.D., CEO of Enveric Biosciences. “We continue to de-risk EB-003 as we look forward to initiating first-in-human Phase 1 clinical trials and remain committed to meeting the highest standards of safety as we progress towards the clinic.”
